Results 161 to 170 of about 111,871 (303)

Early Dapagliflozin and Melatonin Treatment Ameliorated LV Fibrosis via Suppressing TGF‐β1/Smads and Activating Nrf2‐ARE Signaling in MI Rodent

The Kaohsiung Journal of Medical Sciences, EarlyView.
ABSTRACT This study tested whether combined dapagliflozin (DAPA) and melatonin (Mel) therapy was superior to merely one for ameliorating the left ventricular (LV) fibrosis/remodeling and improving LV ejection fraction (LVEF) in rats after acute myocardial infarction (AMI). In vitro study demonstrated that DAPA treatment significantly suppressed the TGF‐
Jiunn‐Jye Sheu, Jui‐Ning Yeh, Han‐Tan Chai, John Y. Chiang, Chi‐Ruei Huang, Jun Guo, Hon‐Kan Yip   +6 more
wiley   +1 more source

Overexpression of the ERG oncogene in prostate cancer identifies candidates for PARP inhibitor-based radiosensitization. [PDF]

J Clin Invest
Köcher S, Elsesy ME, Moustafa A, Mohammadi W, Perugachi Heinsohn A, Nagaraj Y, Oh-Hohenhorst SJ, Hahn J, Siebels B, Mair T, Burdak-Rothkamm S, Tennstedt P, Simon R, Lange T, Tilki D, Frenzel T, Maurer T, Petersen C, Schlüter H, Bokemeyer C, von Amsberg G, Rothkamm K, Mansour WY.   +22 more
europepmc   +1 more source

PARP inhibitors' revival [PDF]

Nature Biotechnology, 2014
openaire   +1 more source

Proteomic Characterization of AS1411 Reveals ATP6AP1 as a Mediator of Triple‐Negative Breast Cancer Progression

PROTEOMICS, EarlyView.
ABSTRACT Triple‐negative breast cancer (TNBC) is an aggressive subtype of breast cancer characterized by high metastatic potential, poor prognosis, and limited effective therapeutic options. In this study, we investigated the molecular mechanisms underlying the anticancer effects of the nucleolin (NCL)‐targeting DNA aptamer AS1411 using label‐free ...
Ha‐Song Bae, Yun‐Jeong Seo, Eun‐Bi Kim, Hyoung‐Min Park, I‐Hsuan Liu, J. Eugene Lee, Jae‐Young Kim   +6 more
wiley   +1 more source

Challenges in employing overall survival as a primary outcome in ovarian cancer studies: insights from PARP inhibitor trials. [PDF]

Front Oncol
Siegler Y, Matanes E.
europepmc   +1 more source

Molecular and genomic advances in breast cancer: A comprehensive review of predictive and therapeutic innovations

Precision Medical Sciences, EarlyView.
Breast cancer subtypes, estrogen receptor‐positive (ER+), HER2‐enriched, and TNBC, are defined by genomic and epigenetic signatures. Multi‐omics profiling, immunotherapy, liquid biopsy, and AI‐driven radiogenomics enable precision medicine. Tools like Oncotype DX and PAM50 support personalized care.
Samina Malik, Arif Malik, Shahzad Ahmad, Hassan Mohsin, Shazia Iqbal   +4 more
wiley   +1 more source

RECQL1 as a potential therapeutic target for PARP inhibitor-resistant ovarian cancer. [PDF]

Sci Rep
Yoshida H, Li J, Inui H, Rokugawa K, Fujiwara K.   +4 more
europepmc   +1 more source

PARP inhibitors synergize with abiraterone [PDF]

Nature Reviews Clinical Oncology, 2018
openaire   +2 more sources

Socioeconomic and Demographic Factors in Genetic Testing Utilization Among Advanced Prostate Cancer Patients

The Prostate, EarlyView.
ABSTRACT Purpose Germline genetic testing in patients with advanced prostate cancer (PCa) is underutilized and hypothesized to be impacted by socioeconomic and demographic factors. This single institution, retrospective study assessed the association of income and social vulnerability with genetic referrals and testing.
Alexandra T. Skowron, Karen Childers, Courtney M. Rose, Kyle C. McElyea, Avery K. Supernois, Yousuf Hussain, Mohammed Baseer, Sunita Ghosh, Clara Hwang   +8 more
wiley   +1 more source

Enhancing PARP inhibitor efficacy in ovarian cancer: targeting the PI3K/AKT/mTOR pathway. [PDF]

J Ovarian Res
Wang Y, Xia Q, Wang X, Lu Y, Wang S, Jiao Y.   +5 more
europepmc   +1 more source